Akebia Therapeutics (AKBA) Operating Leases (2019 - 2025)

Akebia Therapeutics (AKBA) has 7 years of Operating Leases data on file, last reported at $4.9 million in Q3 2025.

• On a quarterly basis, Operating Leases changed 0.02% year-over-year to $4.9 million in Q3 2025; TTM through Sep 2025 was $4.9 million, a 0.02% change from a year earlier, with the FY2024 full-year figure at $3.5 million, down 60.36% from the prior year.
• Operating Leases for Q3 2025 stood at $4.9 million, up from $671000.0 in the prior quarter.
• Over the last five years, Operating Leases for AKBA reached as high as $37.7 million in Q1 2022 and fell as low as $671000.0 in Q2 2025.
• Historically, Operating Leases has averaged $18.3 million across 5 years, with a median of $16.2 million in 2023.
• Across the five-year window, Operating Leases jumped 67.92% in 2022 and sank 94.15% in 2025, its largest moves.
• Year by year, Operating Leases stood at $33.7 million in 2021, then retreated by 14.07% to $29.0 million in 2022, then plunged by 69.11% to $8.9 million in 2023, then tumbled by 60.36% to $3.5 million in 2024, then surged by 39.16% to $4.9 million in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $4.9 million in Q3 2025, $671000.0 in Q2 2025, and $2.1 million in Q1 2025.